Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

When it comes toin vitrodiagnostic (IVD) technologies, medical device and diagnostic companies have been chomping at the bit to produce the next big innovation. The last few years have seen a surge in IVD technologies in the market, as devic

CARLSBAD, MA, UNITED STATES - Oct 17, 2018 - Marking a milestone in bringing its Oncomine Dx Target Test toEurope,Thermo Fisher Scientifictoday announced that it has CE-IVD marked its next-generation sequencing (NGS)-based solution that scre

Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers. Such a test could help with the overuse and u

Patients living with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or multiple sclerosis must see their health practitioners frequently to check the progression of their conditions and their responses

BGI has analyzed the worlds largest set of genome data from pregnant women, a total of 141,431 expectant mothers from across China. The results from the study were published inCell. The genomic analyses from non-invasive prenatal testing (NI

After setting its sights on a $100 million IPO, CAR-T player Allogene Therapeutics has nearly tripled that, pricing the deal at the high end of the range and raising $288 million. Its stock price leaped as high as 39% on its first day of tra

Its hard to believe its been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it. When the acquisition finally did close, Will All the Abb

Illumina reported recently that its revenues for the third quarter grew 20 percent year over year, driven by growth across its sequencing and microarray products. For the three months ended Sept. 30, the San Diego-based company reported $85

NeoGenomics recently announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics stock. Based in Carlsbad, California, Genoptix specializes on hematology and

Genomics services provider GeneWiz and bioinformatics and genomics company Nashville Biosciences announced recently at the American Society of Human Genetics conference that they are collaborating to combine Nashville Bios BioVU biobank wit